Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer Journal Article
| Authors: | Beylergil, V.; Morris, P. G.; Smith-Jones, P. M.; Modi, S.; Solit, D.; Hudis, C. A.; Lu, Y.; O'Donoghue, J.; Lyashchenko, S. K.; Carrasquillo, J. A.; Larson, S. M.; Akhurst, T. J. |
| Article Title: | Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer |
| Abstract: | OBJECTIVE: Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-F(ab')2-trastuzumab [Ga-DOTA-F(ab')2-trastuzumab] has been developed at our institution as a positron imaging reagent for assessing human epidermal growth factor receptor 2 (HER2) expression status by in-vivo imaging. Initial studies on animals demonstrated promising results in the monitoring of treatment response to heat shock protein 90-targeted drugs that inhibit the client protein HER2. We report here our initial clinical experience in the assessment of the toxicity, pharmacokinetics, biodistribution, and dosimetry profile of Ga-DOTA-F(ab')2-trastuzumab with PET/computed tomography using a mean of 236 MBq/5 mg administered intravenously. MATERIALS AND METHODS: A group of 16 women with breast cancer were enrolled in this study. The one patient who did not receive Ga-DOTA-F(ab')2-trastuzumab was excluded from analysis. Both HER2-negative (n=7) and HER2-positive (n=8) cases were studied. Among the latter, seven had undergone trastuzumab treatment previously and one had not. RESULTS: It was determined that Ga-DOTA-F(ab')2-trastuzumab was well tolerated, with a T of ∼3.6±0.9 h; the critical organ was the kidney, with a mean dose of 0.383 cGy/37 MBq; and tumor targeting was seen in 4/8 patients with HER2-positive disease. CONCLUSION: The reagent is safe, and assessments through additional studies in a better-defined group of patients, using larger administered masses of antibodies, with a better immunoreactive fraction are needed. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. |
| Keywords: | breast cancer; pet/ct; herceptin; 68ga; f(ab0)2-trastuzumab |
| Journal Title: | Nuclear Medicine Communications |
| Volume: | 34 |
| Issue: | 12 |
| ISSN: | 0143-3636 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2013-12-01 |
| Start Page: | 1157 |
| End Page: | 1165 |
| Language: | English |
| DOI: | 10.1097/MNM.0b013e328365d99b |
| PROVIDER: | scopus |
| PMCID: | PMC3815146 |
| PUBMED: | 24100444 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 December 2013" - "CODEN: NMCOD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
116Morris -
905Hudis -
778Solit -
265Modi -
139
Akhurst -
11
Lu -
151O'Donoghue -
140Carrasquillo -
67
Smith-Jones -
958Larson -
25Beylergil -
107Lyashchenko
Related MSK Work